Selenium Compounds Inhibit IMPase for Bipolar Disorder
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for bipolar disorder, such as lithium, suffer from toxicity and side effects due to non-specificity and poor bio-permeability, while existing compounds lacking IMPase inhibition activity fail to provide effective alternatives.
Innovation Solution
Development of compounds like ebselen and 2-phenyl-1,2-benzisothiazol-3(2H)-one, which are specific IMPase inhibitors, capable of crossing the blood-brain barrier and offering reduced toxicity, for use in treating bipolar disorder.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If lithium is used to treat bipolar disorder, then therapeutic effectiveness is improved, but toxicity and side effects increase
Solution Approach 1:
The patent changes the chemical structure parameter from lithium salt to organic compound (ebselen and derivatives), maintaining therapeutic effectiveness through IMPase inhibition while altering toxicity parameters to reduce harmful effects
Solution Approach 2:
The patent extracts the essential therapeutic mechanism (IMPase inhibition) from lithium and isolates it in specific organic compounds, separating the desired therapeutic effect from the unwanted toxicity associated with lithium
2Reliability
If lithium is used to treat bipolar disorder, then mood stabilization is achieved, but bio-permeability limitations reduce efficacy
Solution Approach 1:
The patent changes the physical-chemical parameters of the treatment agent from inorganic lithium salt to organic compounds with optimized molecular properties, improving blood-brain barrier penetration while maintaining therapeutic action
3Measurement precision
If existing IMPase inhibitor compounds are developed, then specificity is improved, but poor bio-permeability and inhibition reduce effectiveness
Solution Approach 1:
The patent combines the specific IMPase inhibition mechanism with organic molecular structures that provide both specificity and bio-permeability, creating a composite therapeutic agent that addresses multiple requirements simultaneously
Solution Approach 2:
The patent optimizes molecular parameters of the inhibitor compounds, including lipophilicity and molecular size, to achieve both high enzyme specificity and adequate bio-permeability for effective brain penetration
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds effectively inhibit IMPase, providing a safer and more specific treatment option for bipolar disorder, with ebselen demonstrating bio-availability and low toxicity, potentially replacing lithium in clinical trials.
Implementation Method 1
the ability to inhibit the enzyme inositol monophosphatase (IMPase) is a key factor in the control of bipolar disorder. IMPase catalyses the hydrolysis of inositol monophosphate (IP 1) to inositol
Implementation Method 2
capable of crossing the blood-brain barrier and offering reduced toxicity
Data Source
Figure 1
Figure 2~3
Figure 4~5
AI summary
The invention relates to sulphur- and/or selenium-containing compounds that can inhibit the enzyme inositol monophosphatase (IMPase), and which can be used in treating conditions that are treatable through inhibition of this enzyme, such as bipolar disorder, the compounds having a structure of Formula I, or is a pharmaceutically acceptable salt thereof; Formula I; in which: E is S or Se and each of phenyl rings A and B is optionally substituted with one or more substituents, in which each substituent is selected independently from: (1) a halogen, which is preferably selected from F, Cl and Br; (2) C1-C4 alkyl, such as C1-C2 alkyl or C1 alkyl, optionally substituted with one or more halogen atoms, each of which is preferably selected from F, Cl and Br; and (3) C1-C4 alkoxy, such as C1-C2 alkoxy or C1 alkoxy; optionally substituted with one or more halogen atoms, each of which is preferably selected from F, Cl and Br.